GlassScriptPhysician profile
Prasheeda Bremjit
NPI 1538450176
$959.24
in general payments reported to CMS, 2019-2025
13 companies · $41.14 in 2025
The $41.14 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.50 · 2020: $133 · 2021: $206 · 2022: $88.58 · 2023: $221 · 2024: $199 · 2025: $41.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $192.73 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $182.15 | 2021 | |
| Cvrx, INC. | $168.28 | 2023 | Barostim Neo System |
| Abiomed | $121.14 | 2024 | Impella |
| Medtronic Vascular, INC. | $69.50 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.78 | 2020-2024 | Lifevest |
| Boston Scientific Corporation | $39.21 | 2022-2024 | Watchman Flx |
| Acutus Medical, INC. | $26.49 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $24.57 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $22.17 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.76 | 2023 | Farxiga |
| Kestra Medical Technology Services, INC. | $18.97 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasheeda Bremjit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.